Prise en charge thÃ©rapeutique et suivi des spondylarthrites

More documents

Recommendations

Info

Prise en charge thérapeutique et suivi des spondylarthrites239. Auleley GR, Benbouazza K, SpoorenbergA, Collantes E, Hajjaj-Hassouni N, van derHeijde D, et al. Evaluation of the smallestdetectable difference in outcome or processvariables in ankylosing spondylitis. ArthritisRheum 2002;47(6):582-7.240. Garrett S, Jenkinson T, Kennedy LG,Whitelock H, Gaisford P, Calin A. A newapproach to defining disease status inankylosing spondylitis: the Bath AnkylosingSpondylitis Disease Activity Index. JRheumatol 1994;21(12):2286-91.241. Claudepierre P, Sibilia J, Goupille P, FlipoRM, Wendling D, Eulry F, et al. Evaluation of aFrench version of the Bath AnkylosingSpondylitis Disease Activity Index in patientswith spondyloarthropathy. J Rheumatol1997;24(10):1954-8.242. Jones SD, Calin A, Steiner A. An updateon the Bath Ankylosing Spondylitis DiseaseActivity and Functional Indices (BASDAI,BASFI): excellent Cronbach's alpha scores[letter]. J Rheumatol 1996;23(2):407.243. Calin A, Nakache JP, Gueguen A, ZeidlerH, Mielants H, Dougados M. Defining diseaseactivity in ankylosing spondylitis: is acombination of variables (Bath AnkylosingSpondylitis Disease Activity Index) anappropriate instrument? Rheumatology1999;38(9):878-82.244. Jenkinson TR, Mallorie PA, Whitelock HC,Kennedy LG, Garrett SL, Calin A. Definingspinal mobility in ankylosing spondylitis (AS).The Bath AS Metrology Index. J Rheumatol1994;21(9):1694-8.247. Doward LC, Spoorenberg A, Cook SA,Whalley D, Helliwell PS, Kay LJ, et al.Development of the ASQoL: a quality of lifeinstrument specific to ankylosing spondylitis.Ann Rheum Dis 2003;62(1):20-6.248. Doward LC, McKenna SP, Meads DM,Twiss J, Revicki D, Wong RL, et al. Translationand validation of non-English versions of theAnkylosing Spondylitis Quality of Life (ASQOL)questionnaire. Health Qual Life Outcomes2007;5(7).249. Swinkels A, Dolan P. Spinal positionsense and disease progression in ankylosingspondylitis. A longitudinal study. Spine2004;29(11):1240-5.250. Jauregui E, Conner-Spady B, Russell AS,Maksymowych WP. Clinimetric evaluation ofthe bath ankylosing spondylitis metrology indexin a controlled trial of pamidronate therapy. JRheumatol 2004;31(12):2422-8.251. Viitanen JV, Kautiainen H, Suni J, KokkoML, Lehtinen K. The relative value of spinaland thoracic mobility measurements inankylosing spondylitis. Scand J Rheumatol1995;24(2):94-7.252. Viitanen JV, Kautiainen H, Kokko ML, Ala-Peijari S. Age and spinal mobility in ankylosingspondylitis. Scand J Rheumatol1995;24(5):314-5.253. Dougados M, Gueguen A, Nakache JP,Nguyen M, Amor B. Evaluation of a functionalindex for patients with ankylosing spondylitis[editorial]. J Rheumatol 1990;17(9):1254-5.245. Calin A, Garrett S, Whitelock H, KennedyLG, O'Hea J, Mallorie P, et al. A new approachto defining functional ability in ankylosingspondylitis: the development of the BathAnkylosing Spondylitis Functional Index. JRheumatol 1994;21(12):2281-5.254. Heuft-Dorenbosch L, Spoorenberg A, vanTubergen A, Landewé R, van der Tempel H,Mielants H, et al. Assessment of enthesitis inankylosing spondylitis. Ann Rheum Dis2003;62(2):127-32.246. Haywood KL, Garratt AM, Dawes PT.Patient-assessed health in ankylosingspondylitis: a structured review. Rheumatology2005;44(5):577-86.255. Viitanen JV, Kokko ML, Heikkilä S,Kautiainen H. Neck mobility assessment inankylosing spondylitis: a clinical study of ninemeasurements including new tape methods forcervical rotation and lateral flexion. Br JRheumatol 1998;37(4):377-81.HAS / Service des Bonnes pratiques professionnelles et Service Évaluation médico-économique etsanté publique - septembre 2008-220 -
Prise en charge thérapeutique et suivi des spondylarthrites256. Rahali-Khachlouf H, Poiraudeau S,Fermanian J, Ben Salah FZ, Dziri C, Revel M.Validité et reproductibilité des mesurescliniques rachidiennes dans la spondylarthriteankylosante. Ann Réadapt Méd Phys2001;44(4):205-12.257. Dougados M, Gaudouen Y, Blan M,Boumier P, Raichvarg D, Amor B. Vitesse desédimentation globulaire et immunoglobulinessériques au cours de la pelvispondyliterhumatismale. Rev Rhum 1987;54(3):273-8.258. Spoorenberg A, van der Heijde D, deKlerk E, Dougados M, de Vlam K, Mielants H,et al. Relative value of erythrocytesedimentation rate and C-reactive protein inassessment of disease activity in ankylosingspondylitis. J Rheumatol 1999;26(4):980-4.record keeping in ankylosing spondylitis.Progress report of the ASAS working group. JRheumatol 1999;26(4):951-4.264. Van der Heijde D, Braun J, McGonagle D,Siegel J. Treatment trials in ankylosingspondylitis: current and future considerations.Ann Rheum Dis 2002;61(Suppl 3):iii24-32.265. Zochling J, Braun J. Management andtreatment of ankylosing spondylitis. Curr OpinRheumatol 2005;17(4):418-25.266. Van der Heijde D, Bellamy N, Calin A,Dougados M, Khan MA, van der Linden S.Preliminary core sets for endpoints inankylosing spondylitis. J Rheumatol1997;24(11):2225-9.259. Dougados M, Gueguen A, Nakache JP,Velicitat P, Zeidler H, Veys E, et al. Clinicalrelevance of C-reactive protein in axialinvolvement of ankylosing spondylitis. JRheumatol 1999;26(4):971-4.260. Spoorenberg A, van Tubergen A,Landewé R, Dougados M, van der Linden S,Mielants H, et al. Measuring disease activity inankylosing spondylitis: patient and physicianhave different perspectives. Rheumatology2005;44(6):789-95.267. British Society for Rheumatology, Keat A,Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, et al. BSR guidelines for prescribingTNF-α blockers in adults with ankylosingspondylitis. Report of a working party of theBritish Society for Rheumatology.Rheumatology 2005;44(7):939-47.268. NHS Clinical Knowledge Summaries.Ankylosing spondylitis - management 2008. [consulté le 17-9-2008].261. Wanders AJB, Landewé RBM,Spoorenberg A, Dougados M, van der LindenS, Mielants H, et al. What is the mostappropriate radiologic scoring method forankylosing spondylitis? A comparison of theavailable methods based on the OutcomeMeasures in Rheumatology Clinical Trials filter.Arthritis Rheum 2004;50(8):2622-32.262. Spoorenberg A, de Vlam K, van derLinden S, Dougados M, Mielants H, van deTempel H, et al. Radiological scoring methodsin ankylosing spondylitis. Reliability andchange over 1 and 2 years. J Rheumatol2004;31(1):125-32.263. Van der Heijde D, Calin A, Dougados M,Khan MA, van der Linden S, Bellamy N.Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical269. Rudwaleit M, Listing J, Brandt J, Braun J,Sieper J. Prediction of a major clinicalresponse (BASDAI 50) to tumour necrosisfactor α blockers in ankylosing spondylitis. AnnRheum Dis 2004;63(6):665-70.270. Groupe technique national de définitiondes objectifs. Spondylarthropathies 2003. [consulté le 18-4-2006].271. Haute Autorité de Santé. Polyarthriterhumatoïde : aspects thérapeutiques horsmédicaments et chirurgie - aspects médicosociauxet organisationnels. Saint-Denis LaPlaine: HAS; 2007.272. Khan MA, Khan MK, Kushner I. Survivalamong patients with ankylosing spondylitis: aHAS / Service des Bonnes pratiques professionnelles et Service Évaluation médico-économique etsanté publique - septembre 2008-221 -
Page 5:
Prise en charge thérapeutique et s
Page 8 and 9:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170: Prise en charge thérapeutique et s
Page 219: Prise en charge thérapeutique et s
Page 227: Prise en charge thérapeutique et s
show all

Prise en charge thÃ©rapeutique et suivi des spondylarthrites

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?